Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID03925701

Clinical Study Evaluating the Effectiveness of Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM

Led by Sherief Abd-Elsalam · Updated on 2019-04-29

120

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to evaluate two different drug treatments for people with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (DM). The study compares vildagliptin alone versus a combination of vildagliptin and metformin to see how they affect NAFLD and insulin resistance over six months. It is a phase 3 randomized clinical trial without any masking or blinding. Participants receive either vildagliptin 50 mg twice daily or a combination of vildagliptin and metformin taken twice daily as part of the study treatment. The study lasts for six months during which these medications are taken regularly. Both treatment groups are closely monitored and compared to assess their effects on liver disease and diabetes management. Throughout the study, participants will have assessments to track improvement in NAFLD and insulin resistance. The main outcome measured is the number of patients showing improvement at six months. Participants will be observed regularly for treatment effects and safety, with no mention of long-term follow-up beyond the study period.

CONDITIONS

Brief Title

Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • NAFLD and type 2 DM
Not Eligible

You will not qualify if you...

  • Viral hepatitis
  • Child score more than 6
  • Renal impairment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 6 months

Participants receive either vildagliptin or vildagliptin/metformin twice daily to treat NAFLD with type 2 diabetes.

Regular visits during treatment period

Trial Site Locations

Total: 1 location

1

Tanta University

Tanta, Egypt, 35111

Actively Recruiting

Loading map...

Research Team

S

Sherief Abd-Elsalam, ass. prof.

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here